For research use only. Not for therapeutic Use.
Bortezomib Trimer (CAT: C000588) is a derivative of Bortezomib, which marks a significant advancement in cancer treatment. Bortezomib, the parent compound, is renowned as the first proteasome inhibitor sanctioned by the US FDA for the treatment of multiple myeloma, a type of blood cancer. Bortezomib Trimer stems from this innovation and holds similar potential. Acting as a reversible inhibitor of the 26S proteasome—a crucial protein complex within cells—it targets the ubiquitin-proteasome pathway, a mechanism responsible for protein degradation.
| Catalog Number | C000588 |
| CAS Number | 390800-88-1 |
| Synonyms | N,N’,N”-[2,4,6-Boroxintriyltris[[(1R)-3-methylbutylidene]imino[(1S)-2-oxo-1-(phenylmethyl)-2,1-ethanediyl]]]tris[2-pyrazinecarboxamide]; N,N’,N”-[2,4,6-Boroxintriyltris[[(1R)-3-methylbutylidene]imino[(1S)-2-oxo-1-(phenylmethyl)-2,1-ethanediyl]]]tris-pyrazinecarboxamide; |
| Molecular Formula | C₅₇H₆₉B₃N₁₂O₉ |
| Purity | ≥95% |
| Solubility | DMSO (Slightly), Methanol (Slightly) |
| Appearance | White to Off-White Solid |
| Storage | -20°C, Inert atmosphere |
| Reference | Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009) |
